Pulmatrix (PULM)
(Delayed Data from NSDQ)
$2.31 USD
+0.03 (1.40%)
Updated Aug 12, 2024 10:59 AM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PULM 2.31 +0.03(1.40%)
Will PULM be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PULM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PULM
Pulmatrix, Inc. (PULM) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
HOOKIPA Pharma Inc. (HOOK) Reports Q2 Loss, Lags Revenue Estimates
PULM: What are Zacks experts saying now?
Zacks Private Portfolio Services
UniQure (QURE) Reports Q2 Loss, Misses Revenue Estimates
Amicus Therapeutics (FOLD) Reports Q3 Loss, Misses Revenue Estimates
Other News for PULM
Pulmatrix Announces Executive Changes and New Interim CEO
Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation
Pulmatrix enters cross license agreement with MannKind
MannKind to in-license iSPERSE technology from Pulmatrix
Pulmatrix files for $95M mixed shelf